ProCE Banner Activity

Therapeutic Developments for Relapsed/Refractory Multiple Myeloma: Other Novel Agents With New Targets

Slideset Download

Download these slides to review expert insights on novel agents with new targets for patients with relapsed, refractory MM.

This slideset is intended for clinicians practicing medicine outside of the United States.

Released: July 20, 2020

Expiration: July 19, 2021

No longer available for credit.

Share

Faculty

Katja C. Weisel

Katja C. Weisel, MD

Professor and Leading Physician
University Medical Center Hamburg-Eppendorf
Deputy Director of II. Medical Clinic and Polyclinic, Department of Oncology, Hematology, BMT with Department of Pneumology
Co-Director of University Cancer Center Hamburg
Hamburg, Germany

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

GlaxoSmithKline

Faculty Disclosure

Primary Author

Katja C. Weisel, MD

Professor and Leading Physician
University Medical Center Hamburg-Eppendorf
Deputy Director of II. Medical Clinic and Polyclinic, Department of Oncology, Hematology, BMT with Department of Pneumology
Co-Director of University Cancer Center Hamburg
Hamburg, Germany

Prof. Dr. med. Katja Weisel has disclosed that she has received funds for research support from Amgen, Celgene/Bristol-Myers Squibb, Janssen, and Sanofi and consulting fees from Adaptive Biotech, Amgen, Celgene/Bristol-Myers Squibb, GlaxoSmithKline, Janssen, Karyopharm, Sanofi, and Takeda.